Drug Information

Drug (ID: DG00625) and It's Reported Resistant Information

Name	D-Allosamine
Synonyms	2-Amino-2-Deoxy-Allopyranose; 2-Amino-2-Deoxy-Allopyranoside; 2-Amino-2-Deoxy-Allose; 2-Amino-2-Deoxy-D-Allopyranose; 2-Amino-2-Deoxy-D-Allopyranoside; 2-Amino-2-Deoxy-D-Allose; 2-Deoxy-2-Amino-Allopyranose; 2-Deoxy-2-Amino-Allopyranoside; 2-Deoxy-2-Amino-Allose; 2-Deoxy-2-Amino-D-Allopyranose; 2-Deoxy-2-Amino-D-Allopyranoside; 2-Deoxy-2-Amino-D-Allose; AllN; Allosamine; D-AllN; D-Allosamine; SCHEMBL13985995; C21038; WURCS=2.0/1,1,0/[a2222h-1x_1-5_2*N]/1/ Click to Show/Hide
Structure
Drug Resistance Disease(s)	Disease(s) with Clinically Reported Resistance for This Drug (1 diseases) Head and neck cancer [ICD-11: 2D42] [1]
Target	.	NOUNIPROTAC	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	1
IsoSMILES	C([C@@H]1[C@H]([C@H]([C@H](C(O1)O)N)O)O)O
InChI	InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5+,6 /m1/s1
InChIKey	MSWZFWKMSRAUBD-RSVSWTKNSA-N
PubChem CID	6915732

Type(s) of Resistant Mechanism of This Drug

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Head and neck cancer [ICD-11: 2D42]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)			Click to Show/Hide
Key Molecule: Interleukin 2 receptor subunit alpha (IL2RA)				[1]
Molecule Alteration	Expression		Up-regulation	Molecule Info
Resistant Disease	Head and neck squamous cell carcinoma [ICD-11: 2D42.1]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	PCI-13 cells	Ovary	Homo sapiens (Human)	CVCL_C182
Experiment for Molecule Alteration	Western blotting assay
Experiment for Drug Resistance	MTT assay
Mechanism Description	IL-2Ralpha-expressing cells were significantly more resistant to apoptosis induction by a tripeptidyl proteasome inhibitor (ALLN) and two chemotherapeutic drugs (VP-16 and taxol) than the control or IL-2Rgamma+ cells.IL-2Ralpha overexpression increases cell proliferation rate associated with increasing levels of cell cycle regulatory proteins.

References

Ref 1	Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability .J Cell Biochem. 2003 Jul 1;89(4):824-36. doi: 10.1002/jcb.10557. 10.1002/jcb.10557